Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GQ 1001

Next Previous
Drug Profile

GQ 1001

Alternative Names: GQ-1001; Toxin-DM1-trastuzumab-conjugate

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Conjugate Light; Suzhou GeneQuantum Healthcare
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II HER2 positive breast cancer
  • Phase I Biliary cancer; Breast cancer; Salivary gland cancer; Solid tumours

Most Recent Events

  • 10 Dec 2024 Efficacy and pharmacokinetics data from a phase Ib/II trial in HER2-positive-breast-cancer presented 47th Annual San Antonio Breast Cancer Symposium 2024 (SABCS-2024)
  • 31 May 2024 Efficacy and adverse events data from a phase Ib/II trial in HER2-positive-breast-cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 07 Mar 2024 Phase I development for Biliary cancer, Salivary gland cancer, Breast cancer, Solid tumours and Gastric cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in the US, Australia and China (NCT04450732)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top